Mission
"Provide a new potent brachytherapy tool for the treatment of cancers in humans and animals that will be very effective in improving the lives of these patients."
The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
CURRENT RELEASE
Richland WA, Feb. 06, 2020 (GLOBE NEWSWIRE) --
Vivos Inc. (OTCQB: RDGL), Vivos today announced that the University of Missouri College of Veterinary Medicine will be the first Isopet® regional clinic. The
Isopet® therapy will now be included as a treatment option within their extensive veterinary cancer therapy portfolio. Following our recently completed clinical study of
Isopet® at the University of Missouri’s College of Veterinary Medicine, we are excited to announce that they have agreed to offer Isopet® as a commercially
available therapy option. This makes MU the first regional center to offer Isopet® in addition to our Vista pilot clinic located in the state of WA.
Stock Quote
Links
VIVOS Inc. (OTCQB: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com